Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bengt R Danielsson

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Toxicology and Applied Pharmacology|December 3, 2003
Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmiaBengt R Danielsson, Anna-Carin Sköld, Alf Johansson, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|June 23, 2007
Polytherapy with hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia and teratogenicityChristian Danielsson, Faranak Azarbayjani, Anna-Carin Sköld, et al.
Birth Defects Research|March 5, 2026
Recurrent Constellations of Embryonic Malformations (RCEM): Teratogenicity Linked to Transient Hypoxia and Hormone Pregnancy Tests Agrees With RCEM and Suggest a Reactive Oxygen Species PathogenesisAaron P Adam, Helen E Ritchie, Margaret P Adam, et al.
Current Pharmaceutical Design|November 6, 2007
New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potentialMiriam Karlsson, Bengt R Danielsson, Mats F Nilsson, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|March 4, 2005
Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanismBengt R Danielsson, Alf Johansson, Christian Danielsson, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|February 12, 2011
ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretationBruce K Beyer, Neil Chernoff, Bengt R Danielsson, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Toxicology and Applied Pharmacology|December 3, 2003
Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmiaBengt R Danielsson, Anna-Carin Sköld, Alf Johansson, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|June 23, 2007
Polytherapy with hERG-blocking antiepileptic drugs: increased risk for embryonic cardiac arrhythmia and teratogenicityChristian Danielsson, Faranak Azarbayjani, Anna-Carin Sköld, et al.
Birth Defects Research|March 5, 2026
Recurrent Constellations of Embryonic Malformations (RCEM): Teratogenicity Linked to Transient Hypoxia and Hormone Pregnancy Tests Agrees With RCEM and Suggest a Reactive Oxygen Species PathogenesisAaron P Adam, Helen E Ritchie, Margaret P Adam, et al.
Current Pharmaceutical Design|November 6, 2007
New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potentialMiriam Karlsson, Bengt R Danielsson, Mats F Nilsson, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|March 4, 2005
Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanismBengt R Danielsson, Alf Johansson, Christian Danielsson, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|February 12, 2011
ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretationBruce K Beyer, Neil Chernoff, Bengt R Danielsson, et al.
Pageof 2